Merck & Company

Merck is a global pharmaceutical company that develops and sells prescription medicines, vaccines and animal health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiovascular conditions and other major therapeutic areas. Keytruda, its leading cancer immunotherapy, is a major revenue driver, while Gardasil is another important vaccine franchise. Its Animal Health business provides medicines, vaccines and healthcare solutions for livestock and companion animals.

默克是一家全球领先的制药公司,主要研发和销售处方药、疫苗及动物保健产品。其制药业务专注于肿瘤、传染病、心血管疾病及其他主要治疗领域。Keytruda(可瑞达)是公司的核心癌症免疫治疗药物,也是重要的收入来源;Gardasil(佳达修)则是其另一项重要疫苗产品线。此外,动物保健业务为家畜及伴侣动物提供药物、疫苗和医疗解决方案。

The forecast figures are tipranks’s, read on 2026-11-16 and linked below.

SmartChecker Merck & Company Forecast

The forecast in short

tipranks records 22 analyst ratings on Merck & Company and summarises them as “Moderate Buy”. Their average 12-month price target is USD 162.14 (9.73% Upside). Its tipranks score is 8 out of 10 — Outperform. These are tipranks’s figures as SmartChecker read them on 2026-11-16, not SmartChecker’s own view, and nothing here is advice to buy or sell.

Market cap

USD 364.26 B

≈ RM 1.49T

Share price

USD 147.76

≈ RM 604.77

#40World ranking

tipranks score

Outperform

8

Analyst ratings

Moderate Buy

  • Buy15 68%
  • Hold7 32%
  • Sell0 0%

tipranks’s own summary of the 22 ratings above.

12 months price forecast

USD 162.14 9.73% Upside

USD 97.31 USD 127.38 USD 157.45 USD 187.52Past 12 months 12 months forecast High USD 180 Average USD 162.14 Low USD 1052025-11 2026-11

As tipranks publishes it. SmartChecker has not recalculated any of it.

Investment calculator

Enter a starting amount and your assumed one-year growth rate. Excludes fees, taxes and exchange-rate changes.

Calculator inputs and results
Currency
—
—

Analyst profiles. Who made each call, and when.

AnalystFromPositionTarget priceDated
Carter GouldCantor FitzgeraldHoldUSD 1552026-11-11
Louise ChenScotiabankBuyUSD 1802026-11-10
Trung HuynhRBC CapitalHoldUSD 1402026-11-05
Elmar KrausDZ BANK AGHoldUSD 1532026-11-03
Daina GrayboschLeerink PartnersBuyUSD 1622026-11-02
Ilya ZubkovFreedom Capital MarketsHoldUSD 1402026-11-02
Jason GerberryBank of America SecuritiesBuyUSD 1652026-10-30
Evan SeigermanBMO CapitalBuyUSD 1702026-10-30
Terence FlynnMorgan StanleyBuyUSD 1742026-10-30
Chris SchottJ.P. MorganBuyUSD 1752026-10-30
Vamil DivanGuggenheimBuyUSD 1712026-10-29
Emily FieldBarclaysBuyUSD 1802026-10-28
Geoff MeachamCitiHoldUSD 1452026-10-27
Mohit BansalWells FargoBuyUSD 1652026-10-26
Courtney BreenBernsteinHoldUSD 1052026-10-25
Michael YeeUBSBuyUSD 1752026-10-24
Asad HaiderGoldman SachsBuyUSD 1552026-10-22
Steve ScalaTD CowenHoldUSD 1552026-09-22
Nico ChenDBSBuyUSD 1802026-09-11
Rajesh KumarHSBCBuyUSD 1722026-09-10
Alexandria HammondWolfe ResearchBuyUSD 1802026-08-25
Jasper HellwegArgus ResearchBuyUSD 1702026-08-24
Luisa HectorBerenberg BankHoldUSD 1272026-08-05
Unknown AnalystJefferiesBuyUSD 1382026-05-19
Hans EngelErste GroupHoldN/A2026-05-05
Natalya DaviesRothschild & Co RedburnBuyUSD 1792026-04-17
James ShinDeutsche BankBuyUSD 1502026-02-13
Show moreShow less

Investment Strengths

Diversified product growth多元化产品增长

Revenue growth is supported by multiple therapeutic and animal-health franchises rather than a single product. Continued contributions from new products, oncology and animal health broaden the earnings base and provide durable commercial momentum over the next several quarters.公司的收入增长由多个治疗领域及动物保健业务共同推动,而非依赖单一产品。新产品、肿瘤药物及动物保健业务的持续贡献,有助于扩大整体盈利基础,并在未来几个季度保持稳定且可持续的商业增长动力。

Pipeline strength强大的研发管线

Late-stage clinical and regulatory progress strengthens Merck’s ability to replenish growth as mature products age. Positive results across oncology, vaccines and pulmonary hypertension diversify future launch opportunities and improve the durability of the portfolio.后期临床试验及监管审批方面的持续进展,增强了 Merck 在成熟产品逐渐进入生命周期后补充增长动力的能力。肿瘤治疗、疫苗及肺动脉高压领域取得的积极成果,进一步丰富了公司未来新产品上市的机会,并提升整体产品组合的长期增长潜力。

Strong cash generation强劲的现金创造能力

Substantial operating and free cash flow gives Merck capacity to fund research, launches, capital needs, dividends and business development internally. Strong cash conversion supports financial resilience even while recent free-cash-flow growth has moderated.可观的经营现金流和自由现金流,使 Merck 能够依靠内部资金支持研发、新产品上市、资本支出、股息支付及业务拓展。强劲的现金转化能力为公司提供了稳健的财务基础,即使近期自由现金流增长有所放缓,仍具备较强的财务韧性。

People also ask

What is the 12-month price target for Merck & Company (MRK)?

tipranks publishes an average 12-month price target of USD 162.14 (9.73% Upside), as SmartChecker read it on 2026-11-16. The highest target is USD 180 and the lowest is USD 105. A price target is an analyst’s estimate of where a share might trade, not a promise, and SmartChecker gives no investment advice.

See tipranks’s own page ↗
How many analysts cover Merck & Company (MRK)?

tipranks records 22 analyst ratings: 15 buy, 7 hold and 0 sell, which it summarises as “Moderate Buy”, as SmartChecker read it on 2026-11-16.

See tipranks’s own page ↗
What is the tipranks score for Merck & Company (MRK)?

tipranks scores it 8 out of 10 and calls that “Outperform”, as SmartChecker read it on 2026-11-16. The score is tipranks’s, not SmartChecker’s, and SmartChecker does not rate listed shares.

See tipranks’s own page ↗
Is this SmartChecker’s own forecast for Merck & Company?

No. Every figure on this page is published by tipranks, copied on 2026-11-16 with a link to the original, and not recalculated. SmartChecker assesses financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.

See tipranks’s own page ↗

Member reviews. Members’ own ratings and words, not SmartChecker’s rating.

These ratings and words are written by SmartChecker members and published immediately without administrator approval. SmartChecker does not rate listed companies: a rating here belongs to whoever wrote it, it counts towards no score of ours, and nothing in it is advice.

Disclaimer

SmartChecker provides informational and financial market news only and does not provide investment, financial or legal advice.

tipranks — Merck & Company (MRK)